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Abstract
Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1), which is thought to be produced mainly by
activated hepatic stellate cells and Kupffer cells in the liver, plays a pivotal role in matrix remodeling during liver
injury and repair; while the effect of TIMP-1 on hepatocellular damage remains obscure.
Results: Hepatic expression of TIMP-1 mRNA and protein was up-regulated both in acute and chronic liver injury
induced by carbon tetrachloride (CCl4). Compared with wild-type mice, TIMP-1 knockout mice were more
susceptible to CCl4-induced acute and chronic liver injury, as shown by higher levels of serum alanine
aminotransferase (ALT), greater number of apoptotic hepatocytes, and more extended necroinflammatory foci.
TIMP-1 knockout mice also displayed greater degree of liver fibrosis after chronic CCl4 injection when compared
with wild-type mice. In vitro treatment with TIMP-1 inhibited cycloheximide-induced cell death of primary mouse
hepatocytes. Finally, up-regulation of TIMP-1 in the liver and serum after chronic CCl4 treatment was markedly
diminished in hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) knockout mice. In vitro
treatment with interleukin-6 stimulated TIMP-1 production in primary mouse hepatocytes, but to a lesser extent in
STAT3-deficient hepatocytes.
Conclusions: TIMP-1 plays an important role in protecting against acute and chronic liver injury and subsequently
inhibiting liver fibrosis induced by CCl4. In addition to activated stellate cells and Kupffer cells, hepatocytes are also
responsible for TIMP-1 production during liver injury via a STAT3-dependent manner.
Introduction
Chronic liver fibrosis induced by viral hepatitis, alcohol
abuse, and nonalcoholic steatohepatitis is a major cause
of morbidity and mortality worldwide [1]. The progres-
sion of liver disease can be defined as an alteration of
hepatic parenchyma characterized by two major events:
injury and regeneration. The initial cause of the injury
determines the loss of hepatocytes including apoptosis
a n dn e c r o s i sf o l l o w e db yi n f l a m m a t o r yr e s p o n s e[ 2 ] .
Consequently, the loss of tissues or liver injury leads
viable hepatocytes to re-enter the cell cycle and divide
by mitosis, to replace the lost or damaged hepatocytes
[3]. During these wound healing processes, the extracel-
lular matrix (ECM) also undergoes a process of remo-
deling stimulated by persisting inflammatory injury,
which may result in abnormal collagen deposition [1].
This microenvironment alteration responsible for hepa-
tocyte damage and ECM remodeling is highly complex
and its mechanisms are not fully understood. It seems
that all types of liver cells and a variety of soluble fac-
tors are involved in the process of ECM remodeling,
contributing to hepatocyte injury, inflammation, fibrosis
and liver regeneration [4-8].
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inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs) play an important role in inducing and pre-
venting the degradation of the ECM, respectively [9].
Many studies have shown that MMPs and TIMPs play a
pivotal role in matrix remodeling during hepatic injury
and repair [5,8,10-12]. Among them, TIMP-1 is a widely
expressed, and secreted protein that plays a critical role
in tissue remodeling via inhibiting members of a large
family of MMPs [13]. TIMP-1 has been suggested to be
a serum marker for liver fibrosis, and the expression is
induced during liver injury [14]. In addition, TIMP-1
also plays an important role in promoting liver fibrosis
[15-17] but inhibiting liver regeneration [6]. The profi-
brogenic effects of TIMP-1 are thought to be mediated
via preventing collagen degradation through inhibition
of MMPs and protecting against activated hepatic stel-
late cell (HSC) death [17-20]. It is believed that activated
HSCs and Kupffer cells are the major sources for TIMP-
1 production during liver injury [21]. Although early
studies also showed TIMP-1 mRNA and protein expres-
sion are up-regulated by inflammatory cytokines in rat
hepatocytes [22,23], the precise roles of TIMP-1 pro-
duced by hepatocytes in liver injury remain largely
unknown. In this study, we found that TIMP-1-deficient
(TIMP-1
-/-)m i c ew e r em o r es u s c e p t i b l et oC C l 4-
induced liver injury and fibrosis, suggesting the protec-
tive feature of TIMP-1 in liver injury. Moreover, in vitro
experiments showed that TIMP-1 directly protected
against cycloheximide-induced hepatocyte death. Lastly,
we provided evidence suggesting that hepatocytes also
contribute to TIMP-1 production during chronic liver
injury, which is controlled by STAT3.
Results
Up-regulation of TIMP-1 in acute and chronic liver injury
after CCl4 exposure
To determine the expression of TIMP-1 during the
course of acute and chronic liver injury, real-time PCR
and ELISA analyses were performed on liver samples. As
shown in Figure 1A, in a murine model of acute liver
i n j u r yi n d u c e db yas i n g l ed o s eo fC C l 4 injection, hepatic
TIMP-1 mRNA expression was markedly up-regulated
with a peak 24 h post CCl4 injection. Serum levels of
TIMP-1 protein were also significantly elevated after
CCl4 injection, and were maximal 24 h after injection.
Figure 1B shows the hepatic and serum levels of TIMP-1
after a 4-week CCl4 treatment. Expression of TIMP-1
mRNA in the liver was about 30 and 20 folds higher at
24 and 48 h following the last CCl4 injection, respectively,
as compared to corresponding vehicle-treated mice.
Similarly, serum levels of TIMP-1 protein were also sig-
nificantly higher in CCl4-treated mice than in control
animals. To further determine the source of TIMP-1
production after CCl4 challenge, immunohistochemistry
staining for TIMP-1 in liver tissue sections were per-
f o r m e d .F i g u r e1 Cs h o w st h a tas i n g l ei n j e c t i o no fC C l 4
induced markedly TIMP-1 expression in wild-type mice
with predominant expression around necroinflammatory
areas and weak staining in hepatocytes, while chronic
CCl4 treatment significantly upregulated expression of
TIMP-1 in hepatocytes and nonparenchymal cells. As
expected, no TIMP-1 expression was detected in TIMP-
1
-/- after CCl4 injection. These data show that hepatic
and serum levels of TIMP-1 are markedly elevated after
acute and chronic CCl4 treatment.
TIMP-1
-/- mice are more susceptible to acute liver injury
induced by CCl4 administration
Although it has been reported that TIMP-1 plays an
important role in liver fibrosis and regeneration
[6,15-17], its function during hepatocellular injury
remains unclear. Figure 2 compared the acute liver
i n j u r yi n d u c e db yas i n g l ed o s eo fC C l 4 injection
between TIMP-1
-/- and wild-type mice. All animals sur-
vived after a single dose of CCl4 challenge. Figure 2A
show that acute injection of CCl4 administration
induced higher levels of serum ALT and AST in TIMP-
1
-/- mice than those in wild-type mice. Consistent with
serum ALT levels, TIMP-1
-/- mice also had larger areas
of necrosis than wild-type mice, as assessed by H&E
staining (Figure 2B). In addition, acute CCl4 administra-
tion caused necroinflammatory liver damage with foci
located predominantly in pericentral regions in wild-
type mice, while TIMP-1
-/- mice had a dramatic exacer-
bation of liver damage with widespread foci of necrotic
hepatocytes. Moreover, TUNEL assay shows that TIMP-
1
-/- mice had a higher number of apoptotic hepatocytes
compared with wild-type mice (Figures 2C-D).
TIMP-1
-/- mice are more susceptible to CCl4-induce
chronic liver injury and fibrosis
It is well established that activation of HSCs is a key
event in the pathophysiology of hepatic fibrosis and is
accompanied by induction of TIMP-1 [24,25]. In addi-
tion, administration of a TIMP-1 antibody attenuated
CCl4-induced liver fibrosis [15], thus we hypothesized
that deletion of TIMP-1 may reduce liver fibrosis after
chronic CCl4 exposure. To test this hypothesis, wild-type
and TIMP-1
-/- mice were treated with CCl4 for 4 weeks.
Surprisingly, the grade of liver fibrosis was higher in
TIMP-1
-/- mice with predominant bridging in morphol-
ogy than that in wild-type mice, which was determined
by Sirius red staining for collagen (Figure 3A). Further-
more, immunostaining and Western blot analyses show
that expression of a-SMA, a marker for HSC activation,
was higher in livers from TIMP-1
-/- mice compared with
wild-type animals (Figures 3B and 3C).
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Page 2 of 10To understand the mechanisms underlying the higher
liver fibrosis in TIMP-1
-/- mice than in wild-type mice,
the degree of injury was compared between these two
strains of mice after chronic CCl4 challenge. In
agreement with the greater liver damage in TIMP-1
-/-
mice after acute CCl4 exposure, repeated exposure of
TIMP-1
-/- mice to CCl4 for 4 weeks induced higher
levels of ALT, larger area of necrotic hepatocytes, and
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Figure 1 Up-regulation of hepatic and serum TIMP-1 levels following CCl4-induced acute or chronic liver injury in mice. A,M i c ew e r e
treated with a single dose of CCl4 injection or vehicle (olive oil) injection. Liver tissues were then collected and subject to real-time PCR analysis
of hepatic TIMP-1 mRNA (top panel). Sera were collected for measurement of TIMP-1 protein by ELISA (low panel). B, Mice were treated
chronically with CCl4 or vehicle (olive oil) for 4 weeks. Liver tissues and sera were collected 24 and 48 h after the last injection and subject to
real-time PCR (top panel) and ELISA analyses (low panel) of TIMP-1. The values from vehicle-treated group were set as 1 fold in real-time PCR
analyses. Values represent means ± SEM (n = 4). *P < 0.05; **P < 0.01 in comparison with corresponding vehicle-treated groups. C, Wild-type
(WT) and TIMP-1
-/- mice were treated with CCl4 for 48 hours or 4 weeks. Liver tissues were collected for immunohistochemical staining with anti-
TIMP-1 antibody. Representative pictures are shown (original magnification × 200).
Wang et al. Cell & Bioscience 2011, 1:14
http://www.cellandbioscience.com/content/1/1/14
Page 3 of 10higher number of apoptotic hepatocytes when compared
with those in wild-type mice (Figures 4A-B).
TIMP-1 directly protects against hepatocyte death in vitro
As TIMP-1
-/- mice are more susceptible to CCl4-
induced liver injury, we hypothesized that TIMP-1 may
protect against hepatocyte death. We further tested this
hypothesis in cultured hepatocytes. As illustrated in
Figure 5, incubation of primary hepatocytes with cyclo-
heximide induced hepatocyte cell death as evidenced by
an increase in AST release. Pretreatment with TIMP-1
significantly prevented cycloheximide-induced hepato-
cyte death (Figure 5).
IL-6 up-regulates TIMP-1 mRNA and protein in primary
cultured hepatocytes via a STAT3-dependent manner
It is believed that TIMP-1 is produced mainly by acti-
vated HSCs and Kupffer cells [21], it is not clear
whether hepatocytes also contribute to TIMP-1 produc-
tion. IL-6 has been shown to up-regulate TIMP-1
expression in HSCs and Kupffer cells [26,27]. Here we
also demonstrated that treatment of wild-type mouse
hepatocytes with IL-6 markedly up-regulated expression
of TIMP-1 mRNA hepatocytes, and reaching its highest
level at 6 h (Figure 6A). TIMP-1 protein levels in
the supernatant were also significantly elevated in IL-6-
treated wild-type hepatocytes compared to those with-
out IL-6 treatment (Figure 6B). Moreover, expression of
TIMP-1 mRNA (Figure 6A) and protein (Figure 6B) was
markedly lower in the hepatocyte from STAT3
Hep-/-
mice than those from wild-type mice without or with
IL-6 treatment.
Deletion of STAT3 in hepatocytes reduces hepatic and
serum levels of TIMP-1 after chronic CCl4 treatment
To further confirm the critical role of hepatocyte
STAT3 in the induction of TIMP-1 during chronic liver
injury in vivo, we compared the production of TIMP-1
between wild-type and STAT3
Hep-/- mice 6 and 24 h
after a 4-week chronic CCl4 treatment. As shown in
Figure 7A, hepatic expression of TIMP-1 mRNA was
lower in STAT3
Hep-/- mice as compared to wild-type
mice 24 h after the last CCl4 injection, while the expres-
sion of TIMP-2, TIMP-3, and MMP-9 was comparable
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Figure 2 TIMP-1
-/- mice are more susceptible to CCl4-induced acute liver injury. A, B, Wild-type and TIMP-1
-/- mice were treated with CCl4
for 12 or 24 hours. Serum ALT levels were assayed (A). The liver tissue sections were stained with H&E. Representative pictures are shown
(original magnification × 100) (B). C, D, TUNEL positive hepatocytes were counted (C) and representative pictures of TUNEL staining are shown
(D). Values represent means ± SEM (n = 6-10) *P < 0.05.
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Page 4 of 10between these 2 groups. Serum levels of TIMP-1 protein
were also lower in STAT3
Hep-/- mice 24 h and 48 h post
the last injection of CCl4 than those in wild-type mice
(Figure 7B).
Discussions
Although the profibrotic effect of TIMP-1 mainly pro-
duced by HSCs has been well documented [15,19], we
reveal here for the first time an unexpected hepatopro-
tective feature of TIMP-1 and contribution of hepato-
cytes to TIMP-1 production during CCl4-induced liver
injury.
Hepatoprotection of TIMP-1: dual roles of TIMP-1 in liver
fibrosis
TIMP-1
-/- mice were more susceptible to hepatocelluar
damage induced by CCl4 treatment, suggesting that
TIMP-1 plays a hepatoprotective role during liver injury.
Such hepatoprotection is mediated, at least in part, via
directly inhibiting hepatocyte death as TIMP-1 treatment
prevented cycloheximide-induced hepatocyte damage
(Figure 5). At the present, the mechanism underlying
TIMP-1 hepatoprotection remains unknown. TIMP-1 is
a survival factor for many cell types dependent and/or
independent of the MMP-inhibitory activity [13]. For
example, TIMP-1 inhibits HSC apoptosis via MMP inhi-
bition [19], while the anti-apopotic effect of TIMP-1 on
human breast carcinoma cells does not require MMP
inhibition [28]. Further studies will be required to investi-
gate the mechanism underlying the anti-apoptotic effect
of TIMP-1 on hepatocytes.
TIMP-1 has been suggested as a profibrogenic factor
to promote liver fibrosis as liver-specific TIMP-1 trans-
genic mice were resistant to fibrosis resolution [16] and
TIMP-1 neutralizing antibody inhibited liver fibrosis
[15]. However, surprisingly, TIMP-1
-/- mice developed
greater fibrosis compared with wild-type mice after CCl4
challenge (Figure 3). As TIMP-1 protects against HSC
death [19] and hepatocyte apoptosis (Figure 5), we spec-
ulate that TIMP-1 may have dual roles in liver fibrosis:
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Page 5 of 10stimulating liver fibrosis via promoting HSC survival
and inhibiting liver fibrosis via preventing liver injury.
The final effect of TIMP-1 on liver fibrosis is deter-
mined by the balance between these stimulatory and
inhibitory effects. Deletion of TIMP-1 may reduce liver
fibrosis through abolishing the profibrogenic effect of
TIMP-1, but may also accelerate liver fibrosis by
increasing liver injury. Acceleration of liver fibrosis by
increased liver injury in TIMP-1
-/- mice may dominate
over the profibrogenic effect of TIMP-1 on liver fibrosis,
leading to greater liver fibrosis in TIMP-1
-/- mice after
CCl4 treatment.
Hepatocytes contribute to TIMP-1 production during liver
injury: controlled by STAT3
Expression of TIMP-1 is induced in the liver during
liver injury. It is generally believed that activated HSCs
and Kupffer cells are the major source of TIMP-1 pro-
duction as strong TIMP-1 immunostaining was detected
in activated HSCs and Kupffer cells [21]. Our findings
here suggest that hepatocytes also contribute signifi-
cantly to TIMP-1 production that is controlled by
STAT3. As shown in Figure 7, serum and hepatic levels
of TIMP-1 were lower in STAT3
Hep-/- mice, suggesting
that activation of STAT3 in hepatocytes plays an impor-
tant role in induction of TIMP-1 during liver injury.
This induction is likely due to the direct stimulation of
TIMP-1 production in hepatocytes by STAT3 as in vitro
IL-6 treatment induced TIMP-1 production in cultured
hepatocytes [23,29] and such induction was diminished
in STAT3-deficient hepatocytes (Figure 6). In addition,
STAT3 binding sites were found on TIMP-1 promoter
[30], providing a molecular basis for STAT3-mediated
induction of TIMP-1. Finally, the conclusive evidence
for contribution of hepatocytes to TIMP-1 production is
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the livers of mice with acute and chronic CCl4 treat-
ment. Collectively, these findings suggest that in addi-
tion to HSCs and Kupffer cells, hepatocytes are also a
source for TIMP-1 production which is controlled par-
tially by STAT3 during chronic liver injury.
In summary, our observations collectively identify
n e w l yh e p a t o p r o t e c t i v er o l eo fT I M P - 1i nap o s i t i v e
feedback manner during liver injury, which is regulated
by IL-6/STAT3 signaling pathway. TIMP-1 plays dual
roles in regulating liver fibrosis by inhibiting liver fibro-
sis via protecting against liver injury or by promoting
liver fibrosis via protecting against HSC death.
Materials and methods
Mice
Eight- to ten-week-old male TIMP-1
-/- mice and their
wild-type control C57BL/6 mice were purchased from
the Jackson laboratory (Bar Harbor, Maine). Hepatocyte-
specific STAT3 knockout mice (AlbCre
+/-STAT3
flox/flox)
(STAT3
Hep-/-) and their littermate wild-type controls
(AlbCre
-STAT3
flox/flox) were described previously [31].
All animal experiments were approved by the Institu-
tional Animal Care and Use Committee of the NIAAA.
CCl4-induced liver injury
For acute CCl4-induced liver injury, mice were injected
(i.p) with a single dose of CCl4 (2 ml/kg body weight of
10% CCl4 dissolved in olive oil). For chronic CCl4 stu-
dies, mice received CCl4 injection (2 ml/kg body weight
of 10% CCl4) 3 times a week for up to 4 weeks. Control
groups were treated with vehicle (100% olive oil, 2 ml/
kg). In chronic studies, the mice were sacrificed at dif-
ferent time points after the last injection of chronic
CCl4 treatment.
Blood chemistry
Serum alanine transaminase (ALT) and aspartate amino-
transferase (AST) were determined using a chemistry
analyzer (PROCHEM-V; Barrow-in-Furness, UK). Serum
TIMP-1 levels were assessed by Quantikine enzyme-
linked immunosorbent assay (ELISA) kits (R&D Sys-
tems, Minneapolis, MN).
Histological analysis
Formalin-fixed liver samples were processed, and paraffin-
embedded liver tissue sections were stained with hematox-
ylin and eosin (H&E). Liver fibrosis was determined by Sir-
ius Red staining for collagens or immunohistochemical
staining for activated HSCs with anti-a-smooth muscle
actin (a-SMA) (Dako, Carpinteria, CA), and were quanti-
fied by digital imaging with NIH Scion Image and Adobe
Photoshop (San Jose, CA). Expression of TIMP-1 in the
liver was measured by immunohistochemical staining with
anti-TIMP-1 antibody (R&D Systems).
TUNEL assay
Hepatocyte apoptosis was detected by using an Apoptag
Apoptosis Detection Kit (Chemicon International,
Temecula, CA) as previously described [32].
Real Time PCR
Total RNA was purified from about 30 mg liver samples
according to the manufacturer (Qiagen, Valencia, CA)
and then 1 μg mRNA was reverse-transcribed to cDNA
using a High Capacity cDNA Reverse Transcription kit
(Invitrogen, Carlsbad, CA). The cDNA template was
diluted 1:5 and amplified in real-time PCR using iTaq
SYBR Green Supermix (Bio-rad, Hercules CA). An
initial denaturation at 95°C for 3 min was followed with
PCR cycling: 95°C (15 sec), and 58°C (30 sec) for 40
cycles. Relative mRNA levels were calculated by means
of 2
-ΔΔCT (ΔΔCT = difference of crossing points of test
samples and respective control samples as extracted
from amplification curves by the LightCycler software)
after normalization to 18S expression used as an inter-
nal standard. Fold inductions of analyzed mRNA expres-
sion were normalized on 18S RNA expression. The
sequences of primers were described previously [31].
Western blotting
Liver homogenates were prepared in RIPA buffer
(50 mM Tris; 1% NP40; 0.25% Deoxycholic acid sodium
salt; 150 mM NaCl; 1 mM EGTA) containing 1 mM
Na3VO4 and a protease inhibitor cocktail (Sigma, St.
Louis, MO). Protein concentrations were quantified with
a detergent compatible protein assay kit (Bio-Rad
Laboratories) according to the manufacture’sm a n u a l .
Fifty μg of total protein extracts were denatured in
Laemmli buffer containing 5% b-mercaptoethanol, then
loaded and separated by gel electrophoresis on a 7%
Bis-Tris gel (Invitrogen). Primary antibody was incu-
bated at 4°C overnight under shaking conditions. Immu-
noreactive bands were visualized on nitrocellulose
membranes using alkaline-phosphotase-linked anti-
mouse or rabbit antibody and the ECF detection system
with a PhosphorImager (GE Healthcare, Piscataway, NJ).
Mouse monoclonal anti-a-SMA antibody was obtained
from Sigma-Aldrich. Mouse monoclonal anti-GAPDH
antibody was obtained from Cell Signaling Technology
(Danvers, MA).
Hepatocyte culture and treatment
Mouse hepatocytes were isolated by in situ collagenase
perfusion method [31]. Hepatocytes (2 × 10
5 cells/per
well) were cultured in 6-well plates with serum-free
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the measurement of TIMP-1 protein in culture medium.
The hepatocytes were also cultured in medium contain-
ing 5% serum and treated with cycloheximide (100 μM)
(Sigma) in the presence or absence of recombinant mur-
ine TIMP-1 (100 ng/ml or 200 ng/ml). Cycloheximide
was used to induce hepatocyte apoptosis. Hepatocyte
death was quantified by measuring the activity of
released AST in culture medium.
Statistical Analysis
Data are expressed as means ± SEM (N = 5-12 in each
group). Student t test was performed to compare values
from 2 groups. To compare values obtained from three
or more groups, 1-factor analysis of variance (ANOVA)
was used, followed by Tukey’s post hoc test. Statistical
significance was taken at the P < 0.05 level.
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